AcuCort signs its first commercial agreement for the company's drug Zeqmelit™
The agreement gives Kamada the exclusive right to the marketing and sales as well as the distribution of AcuCort's drug Zeqmelit for, among other things, the treatment of acute allergy on the Israeli market.
- The agreement gives Kamada the exclusive right to the marketing and sales as well as the distribution of AcuCort's drug Zeqmelit for, among other things, the treatment of acute allergy on the Israeli market.
- Under the terms of the agreement, Kamada is responsible for the commercialization of Zeqmelit in Israel and has the exclusive right to marketing, sales, and distribution of the drug in this market.
- The agreement is a historic and commercial milestone for AcuCort.
- It is also a confirmation that AcuCort's innovative drug Zeqmelit is commercially interesting and attracts partners," says Jonas Jnmark, CEO of AcuCort AB.